Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Brokerages

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $46.29.

PVLA has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Canaccord Genuity Group reduced their price target on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Scotiabank assumed coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Jones Trading initiated coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $45.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 target price for the company.

Palvella Therapeutics Stock Down 4.5%

Shares of NASDAQ PVLA traded down $1.17 during mid-day trading on Friday, hitting $25.06. 92,386 shares of the company traded hands, compared to its average volume of 69,303. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The firm has a market cap of $277.06 million, a PE ratio of -2.07 and a beta of -0.10. The business's 50 day moving average is $23.51.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $2.66. As a group, equities analysts expect that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 2,500 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $20.13 per share, with a total value of $50,325.00. Following the completion of the transaction, the director now owns 183,171 shares in the company, valued at $3,687,232.23. The trade was a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PVLA. BML Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter valued at $506,000. Geode Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter valued at about $171,000. ADAR1 Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter valued at about $1,736,000. Renaissance Technologies LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter worth about $256,000. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth about $3,001,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.